Citigroup Inc Lexicon Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 89,745 shares of LXRX stock, worth $68,206. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,745

Previous 33,130 170.89%

Holding current value

$68,206

Previous $55,000 154.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.51 - $2.39 $85,488 - $135,309	56,615 Added 170.89%	89,745 $140,000
Q2 2024 Aug 12, 2024	BUY	$1.54 - $2.28 $23,996 - $35,526	15,582 Added 88.8%	33,130 $55,000
Q1 2024 May 10, 2024	SELL	$1.3 - $3.58 $269,685 - $742,671	-207,450 Reduced 92.2%	17,548 $42,000
Q4 2023 Feb 09, 2024	BUY	$1.0 - $1.53 $188,983 - $289,143	188,983 Added 524.73%	224,998 $344,000
Q3 2023 Nov 09, 2023	BUY	$1.06 - $2.33 $2,679 - $5,890	2,528 Added 7.55%	36,015 $39,000
Q2 2023 Aug 10, 2023	BUY	$2.15 - $3.49 $63,300 - $102,752	29,442 Added 727.86%	33,487 $76,000
Q1 2023 May 11, 2023	SELL	$1.99 - $2.68 $342 - $460	-172 Reduced 4.08%	4,045 $9,000
Q4 2022 Feb 09, 2023	SELL	$1.8 - $2.56 $756 - $1,075	-420 Reduced 9.06%	4,217 $8,000
Q3 2022 Nov 10, 2022	SELL	$1.94 - $3.43 $23,117 - $40,871	-11,916 Reduced 71.99%	4,637 $11,000
Q2 2022 Aug 10, 2022	BUY	$1.31 - $2.69 $10,318 - $21,189	7,877 Added 90.79%	16,553 $31,000
Q1 2022 May 12, 2022	SELL	$1.95 - $3.89 $29,115 - $58,081	-14,931 Reduced 63.25%	8,676 $18,000
Q4 2021 Feb 10, 2022	BUY	$3.81 - $6.16 $55,900 - $90,379	14,672 Added 164.21%	23,607 $93,000
Q3 2021 Nov 10, 2021	BUY	$3.38 - $5.35 $30,200 - $47,802	8,935 New	8,935 $43,000

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $143M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account